Unilife Corp

Unilife — Investor Presentation (November 2016)

13 slides from Unilife's investor presentation, Nov 17, 2016

  1. Slide 1: Industry-Leading Wearable Injectors, People and Partners

    Exhibit 99.1 Industry-Leading November Unilife 17, 2016 Wearable Injectors, People and Partners

  2. Slide 2: Forward-Looking Statements

    Forward This statements. statements We looking These (“SEC”) $5 with Unilife million do presentation key risks not statements on Looking pharmaceutical undertake balance are These and October reasonable uncertainties contains Statements forward-looking of are 24, any the subject 2016, customers obli

  3. Slide 3: Introduction: Industry-Leading Wearable Injectors, People and Partners

    Industry-Leading Introduction An Wearable Large Platforms Fully Customers The Focused Rigorous Strategic Strong Established Unilife Attractive, Industry’s first Right integrated, biopharma partnership 3on pre-filled, collaboration cost injectors support People can programs base controls, Growing Bes

  4. Slide 4: Strengthened Leadership and Board

    Business John President SVP SVP, VP, VP Strengthened Mary Unilife Quality Combination and Ryan Chief GC KateCFO COO Leadership and and Wold, Commercial &Board Secretary CEO Regulatory Ian Michael Products Chair Hanson David with Strong, Rick Ratigan Rosemary Officer Substantial Affairs Hastings Moll

  5. Slide 5: Realigned Company with Disciplined Expense Reduction

    Realigned Number Company Workforce Teams *Focused ^unilife Disciplined Reduction Reductions R&D 300 303 250 Operations 100 Engineers 150 0A 36% 50 Technical $26.4 $9.4 $25.0 $20.0 $17.6 $15.0 $$7.6 $17.0 1st $- Q4Q3 ugust 30.0 10.0 Half 2015 aligned Admin. 200 and $19.3 $8.2 2016 and Includes of Ope

  6. Slide 6: Strategic Partners and Financing

    Strategic Leading $70 Global $75M Exclusive Development Commercial Agreement Minimum Extends Unilife million provided strategic to healthcare-focused Partners and 15 drug signed insupply year programs non-exclusive debt to collaboration and term date infinancing agreement 2014 Customers with underwa

  7. Slide 7: Addressing Market Needs with Wearable Injectors

    Addressing Improving + Reducing E.g. Ease Intuitive products unilife + 1mL of Use steps wherever every Injection Patient Market Improving oftwo use Experience the Frequency Needs weeks with patient Mobility patient- with E.g.is to Reducing Wearable Three health Enabling Optimize E.g.injections ecosy

  8. Slide 8: Significant BioPharma Market Opportunity

    Significant BioPharma Over 12 8prospective 246Phase 0- B *Astra 100 publicly Marketed phase 3 21%Market Suitability Lilly Companies use with II,JNJ available BMS based Phase III Opportunity wearable orwith marketed 2 40% Pre-Registration information on Pfizer Potential criteria GSKor 35% 4% hand-hel

  9. Slide 9: Wearable Injectors Embraced by Industry, Poised for Growth

    Wearable Embraced ••1st Wave Initial Various Lead Injectors by therapies Industry, pharma programs –underway launched Acompanies Poised Significant with in forfirst multi-drug (avg.aMarket Decade generation targets 3-4 yr. Opportunity of Growth wearable select period andinjector preferred from Conso

  10. Slide 10: Unilife Broad, Platform-Based Wearable Injector Portfolio

    Unilife A Precision-Therapy™ 2mL Immediate Mechanical unilife Broad, to Wearable 10mL Platform-Based bolus drive 2mLDelayed Injector force toFlex-Therapy™ 10mL Electromechanical Portfolio or 0.5mL intermittent for to Flex-Therapy™ 2mL any bolus, control Wearable 0.5mL Anyto Electromechanical bolus,

  11. Slide 11: The Unilife Competitive Advantages

    Competitive The + 3Unilife 11+ First Wearable 9to Ready-to-Inject, 9 information Device-related Supplied device Competitor unilife with Advantages user Injectors syringe steps pre-filled prior toFully Competitor to therapy based and useonCustomizable fully A Competitor Device-related publicly Suppli

  12. Slide 12: Looking Ahead: Commercial Path 2017-2020

    Looking An Commercial 2018 Continued 2019 2020 •Targeted Established Existing •Commence Ahead Growth Customer Commence Growth Publicationcustomer Customer Supply Production Commercial Strategy ofsales programs and Commercial Commence for programs results Base Implemented from Clinical complete suppl

  13. Slide 13: Summary: Wearable-Focused Strategy

    Wearable-Focused. Summary Focus 1. Strong 2. Disciplined, 3. Partner 4. Build 5. unilifeprofitable on existing with industry-leading experienced established, base organization Disciplined of customers reliable leadership wearable onLeadership. foundation industry and focused injectors programs leade

Unilife — Investor Presentation (November 2016) on 6ix